Sugi Predict

Sugi Predict / Compounds / SCHEMBL2893510

SCHEMBL2893510

SCHEMBL2893510

Cc1cc(C)n(-c2nc(Nc3ccc(Cl)cc3)cnc2C2OCCO2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCL6 P41182 1/20 0.48
▸ KCNN3 Q9UGI6 2/20 0.41
▸ KCNN2 Q9H2S1 1/20 0.41
▸ TP53 P04637 3/20 0.41
▸ GAA P10253 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ HPGD P15428 1/20 0.40
▸ LMNA P02545 4/20 0.39
▸ MAPK10 P53779 1/20 0.39
▸ NPSR1 Q6W5P4 3/20 0.38
▸ MAPT P10636 2/20 0.38
▸ ALPG P10696 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2891529 0.82 BCL6 (0.53) BCL6KCNN3KCNN2TP53GAA
SCHEMBL2891860 0.82 HTT (0.40) BCL6GAALMNANPSR1POLB
SCHEMBL2890844 0.80 BCL6 (0.54) BCL6KCNN3KCNN2TP53GAA
SCHEMBL2891251 0.77 BCL6 (0.51) BCL6KCNN3KCNN2TP53GAA
SCHEMBL2890777 0.77 BCL6 (0.51) BCL6KCNN3KCNN2TP53GAA
SCHEMBL2885622 0.77 BCL6 (0.51) BCL6KCNN3KCNN2TP53GAA
SCHEMBL2894136 0.76 BCL6 (0.50) BCL6KCNN3KCNN2TP53GAA
SCHEMBL2890629 0.76 BCL6 (0.53) BCL6KCNN3KCNN2TP53GAA
SCHEMBL2891321 0.75 BCL6 (0.49) BCL6KCNN3KCNN2TP53GAA
SCHEMBL3650690 0.75 BCL6 (0.52) BCL6KCNN3KCNN2TP53GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415358-B2 Pyrazine derivatives and their use as potassium channel modulators NEUROSEARCH A/S (DK) 2013-04-09 — — US disclosed
US-8415358-B2 Pyrazine derivatives and their use as potassium channel modulators NEUROSEARCH A/S (DK) 2013-04-09 — — US disclosed
US-20100286161-A1 PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS, INC. 2010-11-11 — — US disclosed
US-20100286161-A1 PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS, INC. 2010-11-11 — — US disclosed
US-20100286161-A1 PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS, INC. 2010-11-11 — — US disclosed
EP-2203436-A1 PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-07-07 — — EP disclosed
WO-2009037247-A1 PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2009-03-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286161-A1 PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS KCNJ2, KCNQ5, KCNA5 BCL6 3342/4885KCNN3 29/4885KCNN2 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.